On September 14, 2026, Q32 Bio Inc. announced the appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer, and Ellie Hershberger, Pharm.D., as Chief Development Officer. The company stated that these appointments come at a pivotal time as it transitions into a late clinical stage company.
Dr. Trevejo brings over 20 years of experience in dermatology and late-stage clinical development. Prior to joining Q32 Bio, he served as Chief Medical Officer and Head of Clinical Pipeline Strategy at Enveda Therapeutics, Inc., where he helped advance a Phase 2 candidate for atopic dermatitis. Before Enveda, he was Chief Medical Officer at Tarsus Pharmaceuticals, where he helped lead the FDA approval and successful launch of XDEMVY, the first FDA-approved treatment for Demodex blepharitis. Earlier in his career, he held leadership roles at Rocket Pharmaceuticals, Cyclerion Therapeutics, Visterra, Genentech, and Vertex Pharmaceuticals.
Dr. Hershberger brings more than 30 years of drug development expertise, with extensive experience overseeing late-stage development operations and regulatory strategy. Prior to joining Q32 Bio, she served as Chief Development Officer of Adagio Therapeutics, now Invivyd, Inc., where she led the development organization and advanced the company’s lead monoclonal antibody candidate from IND-enabling activities through Phase 3 clinical development. She also helped build the development infrastructure to support global approval and contributed to the company’s successful initial public offering, which raised approximately $356 million in gross proceeds. Previously, she held senior clinical development leadership roles at Merck and Cubist Pharmaceuticals.
Q32 Bio is a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. The company is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody, in an ongoing Phase 2 program. Dr. Trevejo noted that bempikibart has shown encouraging results in Part B of the SIGNAL-AA program, demonstrating meaningful hair regrowth and a generally well-tolerated safety profile. The company plans to advance bempikibart into a registration-directed program in alopecia areata in the first half of 2027.
